Edwards Lifesciences (EW) Set to Announce Quarterly Earnings on Thursday

Edwards Lifesciences (NYSE:EW) is scheduled to post its quarterly earnings results after the market closes on Thursday, April 25th. Analysts expect Edwards Lifesciences to post earnings of $0.64 per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same period in the prior year, the company posted $0.64 EPS. The company’s revenue was up 13.3% compared to the same quarter last year. On average, analysts expect Edwards Lifesciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $86.96 on Tuesday. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The company has a market cap of $52.34 billion, a PE ratio of 37.81, a PEG ratio of 4.26 and a beta of 1.05. The company’s 50-day moving average is $90.15 and its two-hundred day moving average is $78.52. Edwards Lifesciences has a 1 year low of $60.57 and a 1 year high of $96.12.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Edwards Lifesciences news, VP Catherine M. Szyman sold 27,000 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the sale, the vice president now directly owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 194,004 shares of company stock worth $17,166,254. 1.27% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wells Fargo & Company raised shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 target price for the company in a research note on Friday, February 2nd. Morgan Stanley upped their price objective on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Finally, Royal Bank of Canada boosted their target price on Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $91.73.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.